Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) EBT Margin (2018 - 2025)

Lipocine (LPCN) has disclosed EBT Margin for 9 consecutive years, with 2781.46% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT Margin changed N/A year-over-year to 2781.46%, compared with a TTM value of 126.66% through Sep 2025, down 7172.0%, and an annual FY2024 reading of 0.08%, up 57365.0% over the prior year.
  • EBT Margin was 2781.46% for Q3 2025 at Lipocine, down from 354.13% in the prior quarter.
  • Across five years, EBT Margin topped out at 11856.66% in Q2 2021 and bottomed at 7037.7% in Q1 2023.
  • Average EBT Margin over 5 years is 308.03%, with a median of 283.58% recorded in 2023.
  • The sharpest move saw EBT Margin crashed -1238301bps in 2022, then skyrocketed 708383bps in 2024.
  • Year by year, EBT Margin stood at 78.48% in 2021, then crashed by -771bps to 526.36% in 2022, then soared by 233bps to 699.55% in 2023, then tumbled by -93bps to 51.04% in 2024, then tumbled by -5549bps to 2781.46% in 2025.
  • Business Quant data shows EBT Margin for LPCN at 2781.46% in Q3 2025, 354.13% in Q2 2025, and 1986.57% in Q1 2025.